Clinical trials: Atherosclerosis, Coronary
Coronary Stenosis, Coronary Artery Disease
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
This is a prospective, multi-center, single-arm, open-label, early feasibility study to provide preliminary evidence for the safety and efficacy of the novel IoNIR stent system
- Trial name
- NCT06071702
- Testing
- IoNIR Ridaforolimus-Eluting Coronary Stent System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medinol Ltd.
Coronary Heart Disease
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
The current study will be conducted to evaluate the real-world effectiveness of inclisiran relative to standard of care (SoC) in Chinese patients with coronary heart disease (CHD), not only with the low-density lipoprotein…
- Trial name
- V-INVINCIBLE (NCT06941792)
- Testing
- inclisiran sodium injection, Standard of Care
- Where
- 19 sites in China
- Volunteers
- 1,590 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary…
- Trial name
- PARAMOUNT (NCT06713239)
- Testing
- Cleerly Labs and Cleerly ISCHEMIA
- Where
- 21 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Cleerly, Inc.
Coronary Artery Disease
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial
The purpose of this study is to compare pharmacokinetics between fixed-dose combination and separate combination of clopidogrel 75mg/aspirin 100mg.
- Trial name
- NCT01496261
- Testing
- Clopidogrel and Aspirin, Fixed dose combination of clopidogrel/aspirin
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Ischemic Heart Disease, Acute Coronary Syndrome
The Israeli MGuard Registry
the objective of the Israeli MGurad Registry is to evaluate the 'Real World' Clinical Performance of the InspireMD MGuard Coronary Stent System
- Conditions
- Ischemic Heart Disease, Acute Coronary Syndrome, Acute Myocardial Infarction
- Trial name
- NCT00922337
- Testing
- MGuard Coronary Stent system
- Where
- 2 sites in Israel
- Volunteers
- 86 people
- Sponsor
- InspireMD
Coronary Artery Disease
Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery
The GTX™ Drug Eluting Coronary Stent System is intended for the treatment of patients with a lesion in the coronary artery.
- Trial name
- NCT00777842
- Testing
- GTX™ Drug Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Cook Group Incorporated
Coronary Artery Disease
A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of…
- Trial name
- EVOLVE48 (NCT03350542)
- Testing
- SYNERGY 48 mm
- Where
- 15 sites in United States, Latvia and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Coronary Heart Disease
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study
The goal of the PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study is to evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected…
- Trial name
- PE-Prove (NCT01148329)
- Testing
- Coronary stenting
- Where
- 40 sites in Austria, Belgium and 9 more
- Volunteers
- 1,010 people
- Sponsor
- Boston Scientific Corporation
Atherosclerosis, Cardiovascular Diseases
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- Trial name
- ACCLAIM-CTA (NCT07613294)
- Testing
- Lepodisiran
- Where
- 57 sites in United States, Australia and 5 more
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Stable Coronary Artery Disease
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease
The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly.
- Trial name
- NCT03384966
- Testing
- Selatogrel
- Where
- 20 sites in United States, Canada and 6 more
- Volunteers
- 346 people
- Sponsor
- Viatris Innovation GmbH
Myocardial Ischemia
Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial
Patients with intermediate-grade coronary stenosis undergo measurement of fractional flow reserve using the test article (Zurich Pressure Guidewire System) and predicate article (Abbott PressureWire System).
- Trial name
- NCT04582877
- Testing
- FFR measurement
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zurich Medical Inc.
Coronary Artery Disease, High-risk Percutaneous Coronary Intervention
Early Feasibility Study of the Supira System in Patients Undergoing HRPCI
The objective of this study is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI.
- Conditions
- Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
- Trial name
- NCT06087575
- Testing
- Supira System
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Supira Medical
Coronary Artery Disease (non-left Main), Coronary Bifurcation Lesion
The European Bifurcation Club Randomized Trial of Stepwise Provisional Stenting Versus Drug Coated Balloon Therapy for Non-left Main True Coronary Bifurcations
Clinical outcomes are worse in patients with coronary artery bifurcation lesions, even if commonly encountered in clinical practice.
- Trial name
- EBC DCB (NCT06822322)
- Testing
- Percutaneous Coronary Angioplasty, Stepwise Provisional Stent Strategy, Drug Coated Balloon Strategy
- Volunteers
- 750 people
- Sponsor
- Ceric Sàrl
Primary Hypercholesterolemia
A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)
This is a study to evaluate the lipid-altering efficacy, safety, and tolerability of ezetimibe when added to ongoing therapy with an 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) in participants…
- Trial name
- NCT03882905
- Testing
- Ezetimibe, Simivastatin, Statin
- Volunteers
- 769 people
- Sponsor
- Organon and Co
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
Myocardial Reperfusion Injury
Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury
The current study aims to evaluate different doses of PC-SOD injections for efficacy and safety in comparison to placebo, in order to provide a basis for future clinical trials in terms of experimental design and dose selection.
- Trial name
- NCT03995732
- Testing
- PC-SOD
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Cardiovascular Disease
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study
The primary objective of this trial is to demonstrate the non-inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited to the estimated 70% of the…
- Trial name
- GeCCO (NCT00995514)
- Where
- United States
- Volunteers
- 4,471 people
- Sponsor
- Medco Health Solutions, Inc.
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia
MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
The purpose of this study is to determine whether MC-1 is effective and safe in reducing cardiovascular and neurological events in patients undergoing high-risk coronary artery bypass surgery
- Conditions
- Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
- Trial name
- NCT00157716
- Testing
- (MC-1) Pyridoxal-5'-phosphate
- Where
- 2 sites in United States, Canada
- Volunteers
- 900 people
- Sponsor
- Medicure
Coronary Artery Disease
Pilot Evaluation Of CORACTO® (THE PILOT-SECRET TRIAL)
The purpose of this study is to evaluate the safety and effectiveness of the CORACTO® (Rapamycin®-Eluting coronary stent delivery system) for the treatment of up to two de novo lesions or restenotic post-PTCA (non-stented)…
- Trial name
- PILOT-SECRET (NCT02076516)
- Testing
- Drug-eluting stent: CORACTO®
- Where
- 5 sites in Belgium, France and 2 more
- Volunteers
- 100 people
- Sponsor
- Alvimedica
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.